Shijiazhuang Yiling Pharmaceutical (002603.SZ)Approval granted for listing application of pomalidomide active pharmaceutical ingredient.

Ling Pharmaceuticals (002603.SZ) announced that its wholly-owned subsidiary, Hengshui Wanyang Hengshui Pharmaceutical Co., Ltd. (referred to as "Hengshui Wanyang"), has received the "Chemical Raw Material Drug Marketing Authorization Approval Notice" issued by the National Medical Products Administration. The application for the marketing of "Pomalidomide" chemical raw materials submitted by Hengshui Wanyang has been approved. According to the announcement, Pomalidomide is a third-generation immunomodulator with immunomodulatory, anti-angiogenic, and anti-tumor effects, which is effective for various malignant hematologic diseases.